SynthesisScientific reports2021
Prevalence of celiac disease in low and high risk population in Asia-Pacific region: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-Analysis and Systematic Review of HLA DQ2/DQ8 in Adults with Celiac Disease.International journal of molecular sciences · 2023Pooled it
- Prevalence of Celiac Disease in China Among High-Risk Populations: A Systematic Review and Meta-Analysis.Journal of digestive diseasesPooled it
- Unraveling the Complexity of Celiac Disease: A Narrative Review of Its Multisystem Nature.Medicina (Kaunas, Lithuania) · 2026Review
- Celiac disease and metabolic syndrome: from risk to a preventive opportunity, in the perspective of children's health.Frontiers in nutrition · 2026Review
- Lactiplantibacillus plantarum Moderating Effect on Autoimmune Celiac Disease Triggers.Probiotics and antimicrobial proteins · 2025Review
- Celiac Disease-Narrative Review on Progress in Celiac Disease.Foods (Basel, Switzerland) · 2025Review
- Utilizing Telemedicine Applications in Celiac Disease and Other Gluten-Free-Diet-Dependent Conditions: Insights from the COVID-19 Pandemic.Healthcare (Basel, Switzerland) · 2024Review
- Gluten-Free Diet and Other Celiac Disease Therapies: Current Understanding and Emerging Strategies.Nutrients · 2024Review
- Celiac Disease Genetics, Pathogenesis, and Standard Therapy for Japanese Patients.International journal of molecular sciences · 2023Review
- Celiac disease in paediatric patients in the United Arab Emirates: a single-center descriptive study.Frontiers in pediatrics · 2023Article
- The modulation of macrophage subsets in celiac disease pathogenesis.Immunity, inflammation and disease · 2022Review
- Celiac Disease Patients With Coronary Artery Disease: A Nationwide Population-Based Study.Cureus · 2022Article
- Article
- Association between intestinal neoplasms and celiac disease: A review.World journal of gastrointestinal oncology · 2021Review
- Celiac disease in the COVID-19 pandemic.Journal of translational autoimmunity · 2021Article
- Celiac disease: Understandings in diagnostic, nutritional, and medicinal aspects.International journal of immunopathology and pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis study was conducted to estimate the pooled prevalence of CD in low and high risk groups in this region. Following keywords were searched in the Medline, PubMed, Scopus, Web of Science and Cochrane database according to the MeSH terms; celiac disease, prevalence, high risk population and Asian-Pacific region. Prevalence studies published from January 1991 to March 2018 were selected. Prevalence of CD with 95% confidence interval (CI) was calculated using STATA software, version 14. The pooled sero-prevalence of CD among low risk group in Asia-Pacific region was 1.2% (95% CI 0.8-1.7%) in 96,099 individuals based on positive anti-tissue transglutaminase (anti-t-TG Ab) and/or anti-endomysial antibodies (EMA). The pooled prevalence of biopsy proven CD in Asia-Pacific among high and low risk groups was 4.3% (95% CI 3.3-5.5%) and 0.61% (95% CI 0.4-0.8%) in 10,719 and 70,344 subjects, respectively. In addition, the pooled sero-prevalence and prevalence of CD in general population was significantly higher in children compared with adults and it was significantly greater in female vs. male (P < 0.05). Our results suggest high risk individuals of CD are key group that should be specifically targeted for prevention and control measures, and screening may prove to have an optimal cost-benefit ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.